ReviewFrontiers in physiology2021
Crescentic Glomerulonephritis: Pathogenesis and Therapeutic Potential of Human Amniotic Stem Cells.
Review in Frontiers in physiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 19 citations in OpenAlex.
- The Src-Family Kinases Hck, Fgr and Lyn Drive Immune Complex-Mediated Glomerulonephritis Through the Syk Tyrosine Kinase.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Article
- Hydrogel-Based Systems in Intrauterine Adhesions: Bridging the Gap from Bench to Bedside.Advanced healthcare materials · 2026Review
- Outcomes and Validation of Histopathological Scores in Pediatric ANCA-vasculitis.Kidney international reports · 2026Article
- Antiglomerular Basement Membrane (Anti-GBM) Glomerulonephritis in the Context of Genitourinary Tuberculosis: A Case Report.Kidney medicine · 2026Article
- Complement-Mediated Kidney Diseases: Role of Alternative Pathway in Glomerular Inflammation.Kidney international reports · 2026Review
- Histopathological spectrum and short-term outcome of rapidly progressive glomerulonephritis in children: a retrospective analysis from a tertiary care center.BMC nephrology · 2025Article
- Biopsy-proven Crescentic Glomerulonephritis Following Inhaled Methamphetamine Use: An Exceptional Case of Confirmed Drug-induced Glomerular Injury.Kidney medicine · 2025Article
- Human amniotic epithelial stem cells, a potential therapeutic approach for diabetes and its related complications.Human cell · 2025Review
- Review
- Article
- The Clinicopathological Correlation and Outcome of Glomerulonephritis With Crescent: A Single-Center Study.Cureus · 2024Article
- Diminished PD-L1 regulation along with dysregulated T lymphocyte subsets and chemokine in ANCA-associated vasculitis.Clinical and experimental medicine · 2023Article
- CD47 blockade ameliorates autoimmune vasculitis via efferocytosis of neutrophil extracellular traps.JCI insight · 2023Article
- Anti-GBM disease with positive serum anti-GBM antibodies but negative IgG deposition: A case report.SAGE open medical case reports · 2023Article
- Extracellular Vesicles Released from Stem Cells as a New Therapeutic Strategy for Primary and Secondary Glomerulonephritis.International journal of molecular sciences · 2022Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic kidney disease (CKD) leads to significant morbidity and mortality worldwide. Glomerulonephritis (GN) is the second leading cause of CKD resulting in end stage renal failure. The most severe and rapidly progressive type of GN is characterized by glomerular crescent formation. The current therapies for crescentic GN, which consist of broad immunosuppressive drugs, are partially effective, non-specific, toxic and cause many serious side effects including infections, cancer, and cardiovascular problems. Therefore, new and safer therapies are needed. Human amniotic epithelial cells (hAECs) are a type of stem cell which are isolated from the placenta after birth. They represent an attractive and novel therapeutic option for the treatment of various inflammatory conditions owing to their unique and selective immunosuppressive ability, as well as their excellent safety profile and clinical applicability. In this review, we will discuss the immunopathogenesis of crescentic GN, issues with currently available treatments and how hAECs offer potential to become a new and harmless treatment option for this condition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.